The mystery of cancer from the perspective of the Eph system

The mystery of cancer from the perspective of the Eph system

The complex relationship between the Eph system and cancer

The Eph system contains 14 tyrosine kinase receptors (9 EphA and 5 EphB receptors) and 8 cell surface-anchored ephrin ligands (5 glycophosphatidylinositol-linked ephrin-A and 3 transmembrane ephrin-B). These receptors and ligands interact to form a complex signal transduction network that regulates cell-to-cell communication. Under normal physiological conditions, the Eph system is involved in tissue development, homeostasis, and regeneration, but in cancer, this system is dysregulated.

The expression of Eph receptors and ephrins in cancer cells may be upregulated or downregulated, and this expression change is consistent with their dual role in cancer progression. For example, in the early stages of some cancers, Eph receptors may be upregulated to promote tumorigenesis, while in the late stages they are downregulated, showing different functions. In addition, the expression of Eph receptors and ephrins can regulate each other, and this regulation may alleviate the tumor suppressive effect of Eph forward signals in some cancers.

Dual Role of Eph System in Cancer Progression

The role of Eph system in cancer is two-sided. On the one hand, forward signaling of Eph receptors usually has the effect of inhibiting cancer progression. For example, forward signaling of EPHA3 and EPHA7 can induce apoptosis in prostate cancer cells, while forward signaling of EPHB2 can impair cell division, leading to multinucleation and apoptosis. On the other hand, non-classical signaling of Eph receptors is usually associated with pro-tumor activities. For example, non-classical signaling of EPHA2 can promote cancer cell invasion and metastasis through multiple mechanisms.

Interaction of Eph system with tumor microenvironment

The Eph system not only plays a role inside cancer cells, but also mediates the mutual communication between cancer cells and cells in the tumor microenvironment (TME). The tumor microenvironment contains a variety of cell types and extracellular matrix (ECM), which support tumor cells during cancer progression. The role of Eph system in tumor angiogenesis is well established, but recent studies have also revealed its role in immune cells, cancer-associated fibroblasts and extracellular matrix.

New targets for cancer treatment

Given the importance of the Eph system in cancer, scientists are exploring cancer treatment strategies targeting Eph receptors and ephrin. These strategies include the use of small molecule kinase inhibitors, antibodies, peptide agonists, and recombinant ephrin. For example, antibodies and peptide drugs targeting EPHA2 have shown good results in preclinical studies. In addition, immunotherapy is also being explored, including the use of Eph receptor peptide fragments as T cell epitopes to induce anti-tumor immunity.

Future research directions

Although some progress has been made, there are still many unknowns about the role of the Eph system in cancer. Future research will focus on better understanding the signaling mechanisms of Eph receptors and ephrin in different cell types and how they affect cancer progression and treatment response. In addition, the expansion of comprehensive omics methods will help identify the best therapeutic targets and targeting strategies.

In summary, the complex role of the Eph system in cancer provides us with new perspectives and potential therapeutic targets. With the deepening of research, we are expected to develop more effective cancer treatments and improve patient outcomes.